1. Home
  2. MEIP vs AMOD Comparison

MEIP vs AMOD Comparison

Compare MEIP & AMOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEIP
  • AMOD
  • Stock Information
  • Founded
  • MEIP 2000
  • AMOD 2014
  • Country
  • MEIP United States
  • AMOD United States
  • Employees
  • MEIP N/A
  • AMOD N/A
  • Industry
  • MEIP Biotechnology: Pharmaceutical Preparations
  • AMOD
  • Sector
  • MEIP Health Care
  • AMOD
  • Exchange
  • MEIP Nasdaq
  • AMOD NYSE
  • Market Cap
  • MEIP 17.1M
  • AMOD 16.7M
  • IPO Year
  • MEIP 2003
  • AMOD N/A
  • Fundamental
  • Price
  • MEIP $1.98
  • AMOD $1.21
  • Analyst Decision
  • MEIP Hold
  • AMOD
  • Analyst Count
  • MEIP 1
  • AMOD 0
  • Target Price
  • MEIP N/A
  • AMOD N/A
  • AVG Volume (30 Days)
  • MEIP 11.6K
  • AMOD 61.9K
  • Earning Date
  • MEIP 05-08-2025
  • AMOD 05-15-2025
  • Dividend Yield
  • MEIP N/A
  • AMOD N/A
  • EPS Growth
  • MEIP N/A
  • AMOD N/A
  • EPS
  • MEIP N/A
  • AMOD 0.13
  • Revenue
  • MEIP N/A
  • AMOD N/A
  • Revenue This Year
  • MEIP N/A
  • AMOD N/A
  • Revenue Next Year
  • MEIP N/A
  • AMOD N/A
  • P/E Ratio
  • MEIP N/A
  • AMOD $9.36
  • Revenue Growth
  • MEIP 33.76
  • AMOD N/A
  • 52 Week Low
  • MEIP $1.46
  • AMOD $1.02
  • 52 Week High
  • MEIP $4.10
  • AMOD $13.49
  • Technical
  • Relative Strength Index (RSI)
  • MEIP 40.20
  • AMOD N/A
  • Support Level
  • MEIP $1.86
  • AMOD N/A
  • Resistance Level
  • MEIP $2.35
  • AMOD N/A
  • Average True Range (ATR)
  • MEIP 0.16
  • AMOD 0.00
  • MACD
  • MEIP 0.02
  • AMOD 0.00
  • Stochastic Oscillator
  • MEIP 68.42
  • AMOD 0.00

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

About AMOD ALPHA MODUS HOLDINGS INC

Alpha Modus Holdings Inc is a technology company with a core focus on artificial intelligence in retail. It is engaged in creating, developing and licensing data-driven technologies to enhance consumers' in-store digital experience at the point of decision.

Share on Social Networks: